SFL Managing Director Provides Further Update Regarding Revision Of EU Medtech Legislation
SFL's Managing Director, Shayesteh Furst-Ladani will be giving presentations at two upcoming Swiss life science events on revision of EU Medtech legislation.
- (1888PressRelease) November 19, 2013 - The environment for medtech in the EU is being profoundly influenced by the revision of EU Medtech Legislation. SFL's Managing Director, Shayesteh Fürst-Ladani, has given a number of presentations at international meetings and published a number of articles regarding potential implications of proposed changes for the medtech industry.
The ongoing debate in the EU is also being closely watched by companies in Switzerland, Europe's leading medtech market. Ms. Fürst-Ladani's recognised expertise in this complex field, which includes serving as chair of the SwAPP (Swiss Association of Pharmaceutical Professionals) Medical Device Task Force, will see her giving presentations at two upcoming Swiss life science events.
On 25 November, Ms. Fürst-Ladani will be presenting at the i-net/BioValley Stammtisch event in Basel and on 27 November, she will speak at the SwAPP Annual Meeting in Bern. In her presentations, as well as examining the major technological and regulatory trends that are shaping the EU's medtech regulatory landscape, she will focus on the practical implications for stakeholders in Switzerland.
"A wide array of companies will be affected by the ongoing legislative changes, including manufacturers of medical devices, in vitro diagnostics, drug/device combination products and borderline products," commented Ms. Fürst-Ladani. "In my presentations, I will address how they can become more adept at interpreting upcoming rules concerning their products, and implement appropriate action for their daily business operations".
Ms. Fürst-Ladani is the Managing Director and founder of SFL. She has comprehensive experience in formulating global regulatory strategies and provides support for the development of drugs, orphan drugs, drug and device combination products, borderline products, medical devices, in vitro diagnostics and advanced therapy medicinal products.
Ms. Fürst-Ladani has been member of the Program Committee of DIA EuroMeetings 2011, 2012, 2013 and 2014 leading the Theme Drugs, Devices, In Vitro Diagnostics and their Combinations. In 2012, she received the Open University Business School's Alumni Award Outstanding "Contribution to an Organization".
A number of her articles regarding medical device regulation and related regulatory areas are available on the SFL website.
About SFL Regulatory Affairs & Scientific Communication Ltd:
SFL provides integrated solutions from the bench to approval and reimbursement within one consultancy, with expertise in Regulatory Affairs, Public Affairs, Legal Services, Medical Communication, HTA, Pricing and Reimbursement. We provide a personalized and integral oversight package. In its deliveries, SFL also considers ethical aspects of appropriate values, norms and principles. SFL conducts portfolio analyses and provide strategic support for products in diverse therapeutic areas. The SFL team works from offices in Switzerland and the United Kingdom, Europe's key locations for healthcare products development.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam